Where does treatment of chronic myeloid leukemia target tyrosine kinase inhibitors?

Abstract

Tyrosine kinase inhibitors (TKIs) now occupy a place in the treatment of chronic myelogenous leukemia (CML), both in monotherapy with the possibility of individualized access, and when used in combination with other drugs - substances that increase their potency. The goal remains to achieve a deep, long-term molecular response with the option of ending the treatment.

This targeted targeted combination therapy will have great potential, there is great hope for the future, but TKI will have its irreplaceable place in CML therapeutic algorithms.

Keywords

• CML
• TKI therapy
• Ph chromosome